We've identified NICE guidance that could generate cost savings.
In some cases, implementing guidance will free up resources and capacity that can be used for other services. This results in improved productivity rather than delivering actual cash savings.
Our resource impact reports and templates (linked in the table below) allow you to more accurately estimate savings for your local setting.
Find out more
|Guidance||Why does this guidance save money?||How will the guidance save money?||
Estimated saving per 100,000 population (£)
Estimated saving for England (£ million)
Savings are anticipated as a result of a shift in diagnostic imaging.
An increase in the number of people receiving CT coronary angiography leads to savings from reduced numbers of people receiving invasive coronary angiography and other diagnostic tests.
|Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)||
The resource impact assessment indicates that there will be a saving from implementing the guidance due to decreased drug costs and the large eligible population. Savings will be less in earlier years due to lower initial uptake of the technology.
|Faecal calprotectin diagnostic tests to differentiate inflammatory bowel disease from irritable bowel syndrome (DG11)||It is anticipated that there will be a cost saving from avoiding referrals to secondary care. This should lead to a reduction in capacity requirements and waiting times for endoscopy/colonoscopy/sigmoidoscopy in secondary care services.||£20,000||£11.1m|
|Virtual chromoendoscopy to assess colorectal polyps during colonoscopy (DG28)||Resource impact work indicates implementation will be cost saving from the avoidance of unnecessary histopathology assessments when assessing colorectal polyps.||
|Spectra Optia for automated red blood cell exchange in patients with sickle cell disease (MTG28)||Savings for commissioners are expected due to the reduced number of people requiring chelation therapy.||£18,100||£12.9|
|HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography (MTG32)||
There may be a significant national saving from the avoidance of unnecessary invasive coronary angiography (ICA) and percutaneous coronary interventions (PCI). The availability of 64-slice CT coronary angiography may be a barrier to realising the savings in full.
There is currently no national tariff for HeartFlow FFRCT and uncertainties around funding flows for provider organisations may be a barrier to implementation of the technology.
Commissioners are encouraged to work with provider organisations to develop a local tariff to establish the use of HeartFlow FFRCT in interventional cardiology service provision.
|Menopause: diagnosis and management (NG23)||
The recommendations should result in a decrease in the number of follicle-stimulating hormone tests being received by women aged 45 years or older and because of this a saving of £9.6 million for England is expected.
Some additional costs may result if women change from using oral to transdermal hormone replacement therapy. These costs are estimated as £0.9 million, resulting in an overall saving of around £8.7 million for England.
There may be savings from reduced inpatient procedures, fewer revision operations being needed, and fewer readmissions following treatment with XprESS. The level of savings depends on how many XprESS procedures are done in an outpatient setting and the device cost of XprESS.
Additional benefits include reducing the number of inpatient bed days needed, and increasing day-case and operating theatre capacity.
There is currently no national tariff for providing XprESS in an outpatient setting. Commissioners are encouraged to work with provider organisations to develop a local tariff.
|PIGF-based testing to help diagnose suspected pre-eclampsia (DG23)||
Implementation of the guideline may lead to a reduction in bed days and increase available clinical time. Current estimates indicate that national savings of around £7.3 million may be possible in year 5. The savings are not anticipated to be cash releasing.
|Bladder cancer: diagnosis and management (NG2)||
Savings are expected to arise from a reduction in the number of people with low risk non-muscle-invasive bladder cancer receiving follow-up cystoscopies in secondary care after 12 months.
|Macular degeneration (wet age-related) - aflibercept (1st line) [ID519] (TA294)||
Aflibercept is associated with fewer treatment and monitoring visits: implementing this guidance is therefore likely to release resources to the NHS. Fewer visits will also reduce the burden on people with wet AMD and their carers in terms of time off work and travel costs.
|SecurAcath for securing percutaneous catheters (MTG34)||
Resource impact work indicates implementation will be cost saving by avoiding or reducing the need to replace adhesive securement devices for PICCs, and are greater the longer a PICC is in place.
|Adjunctive colposcopy technologies for examination of the uterine cervix - DySIS and Niris Imaging System (DG4)||
Use of Dysis may reduce the number of repeat tests and
It is anticipated there may be fewer diagnostic biopsies required, giving pathology test savings,
Future years savings may be achieved through avoiding progression to surgical interventions. Use of Dysis will incur capital costs with some on-going maintenance costs.
|Hypothermia: prevention and management in adults having surgery (CG65)||
Implementing the guideline may result in the following benefits and savings:
|EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing (MTG12)||The expected annual savings and resources released from using EXOGEN 4000+ per 100,000 population aged 18 years and over is around £5,700. This arises from reduced need for surgical intervention and the associated hospital resource use.||£5,700||£2.9m|
|Vision Amniotic Leak Detector (ALD) to eliminate amniotic fluid leakage as a cause of vaginal wetness in pregnancy (MTG15)||
Using the Vision ALD could potentially save between £15 and £24 per women depending on the clinical scenario used. This is mainly a productivity saving resulting from reduced staff time required for administering Vision ALD compared to a speculum test.
|GreenLight XPS for treating benign prostatic hyperplasia (MTG29)||
Savings range from £1.3 million when 36% of procedures with GreenLight XPS are done as day cases, to as much as £3.2 million when 70% are done as day cases. Based on 53% of GreenLight XPS procedures being done as day cases, the guidance is estimated to save the NHS around £2.3 million per year.
|High-throughput non-invasive prenatal testing for fetal RHD genotype (DG25)||
Resource impact work indicates there may be some savings from offsetting the test cost with avoided unnecessary treatment with anti-D immunoglobulin.
Additional benefits include conserving anti-D immunoglobulin stocks and reducing potential adverse events that can be associated with blood product use. Implementation of the guidance will result in savings to providers.
|ENDURALIFE powered CRT-D devices for treating heart failure (MTG33)||
ENDURALIFE-powered CRT-D devices are expected to be
|Assess locally||Assess locally|
|Antimicrobial stewardship: changing risk-related behaviours in the general population (NG63)||Implementation of the guideline is anticipated to be cost saving with a reduction in the inappropriate prescribing of antimicrobials, an increase in the most appropriate use of antimicrobials, a corresponding reduction in the prevalence of antimicrobial resistance and reduced infections.||Assess locally||Assess locally|
|Physical health of people in prison (NG57)||
Implementing the recommendation on medicines reconciliation may generate savings for commissioners by reducing costs related to non-elective attendances and prison escort and bed watching. There may need to be some reallocation of resources within prison healthcare to implement this recommendation.
There are a number of recommendations in the guideline where it may be necessary to invest resources to support early interventions and planned management of conditions for people in prison. This investment may lead to savings from reducing emergency incidents and admissions, unplanned treatments, late presentation of conditions, and morbidity and mortality from infectious and communicable diseases.
|Assess locally||Assess locally|
|The MAGEC system for spinal lengthening in children with scoliosis (MTG18)||The insertion costs of MAGEC rods are estimated to be £27,400, with an annual lengthening cost of £900. In contrast, conventional growth rods are estimated to cost £15,300 for insertion and £5,400 for annual lengthening. The additional insertion cost of £12,100 for the MAGEC system has a payback period of less than 3 years. Anticipated savings per child after 6 years are estimated to be around £12,000.||Assess locally||Assess locally|